Trend Press Wire

Nuclear Medicine Market Projected to Cross $16.2 Billion by 2026

Press release   •   Aug 30, 2019 02:40 EDT

The global Nuclear Medicine Market size is estimated to reach at US$ 16.2 billion by 2026, registering a CAGR of 9.5% from 2018 to 2026, according to a new study by Acumen Research and Consulting.

Market Overview:

Nuclear Medicine Market 2018 - 2026 research report includes the SWOT analysis that's Strengths, Weakness, Opportunities and Threats which provides you complete analysis of competitors, market growth, market share and in addition as CAGR comparison by region. The report provides analysis of the global Nuclear Medicine Market for the period from 2016 to 2026, wherein 2018–2026 is the forecast period and 2018 is the base year. Data for 2017 has been included as historical information.

The report covers all trends and technologies expected to play a major role in growth of the global Nuclear Medicine Market during the forecast period. It highlights drivers, restraints, and opportunities expected to influence the market from 2018 to 2026. The study provides a holistic perspective on the Nuclear Medicine Market, in terms of revenue (in US$ Mn) and volume (in million units), across different regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South America. The report highlights key trends affecting the Nuclear Medicine Market at the global level. Prominent countries/sub-regions covered in the report include the U.S., Canada, Germany, France, the U.K., Italy, Russia, India, China, Japan, South Korea, South East Asia, GCC, South Africa, and Brazil.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1041

The report comprises detailed ecosystem analysis, which provides a comprehensive view of the global Nuclear Medicine Market. Porter’s five forces model has also been included to help understand the competition landscape of the market. Additionally, current indicators of diverse macro-economic factors are contextualized under key market indicators.

The report also analyzes the Nuclear Medicine Market on the basis of various segments. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Scope of the Nuclear Medicine Market Report:

The study provides a decisive view of the Nuclear Medicine Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Segmentation:

Market By Product

  • Diagnostics
    • SPECT
      • TC-99m
      • TL-201
      • GA-67
      • I-123
      • Others
    • PET
      • F-18
      • RB-82
      • Others
    • Therapeutics
      • Alpha Emitters
        • RA-223
        • Others
      • Beta Emitters
        • I-131
        • Y-90
        • SM-153
        • Re-186
        • Lu-117
        • Others
      • Brachytherapy
        • Cesium-131
        • Iodine-125
        • Palladium-103
        • Iridium-192
        • Others

Market By Application

  • Diagnostics
    • Cardiology
    • Neurology
    • Oncology
    • Thyroid
    • Lymphoma
    • Others
  • Therapeutics
    • Thyroid
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumor
    • Others

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

North America initiated the market in 2018, representing an offer of over 44.0% that year. This can be ascribed to progressive healthcare infrastructure in the district, particularly in U.S. Increasing burden of disease and different cardiovascular disarranges is likewise a high effect rendering factor driving the market.

Asia Pacific is foreseen to enroll the most astounding CAGR of 10.9% during the forecast period. Demand for nuclear medicine is expanding in developing markets, for example, China and India because of rising disposable income, enhancing medicinal healthcare standards, and favourable reforms in foreign policies. China is overwhelms the Asia Pacific market and is probably going to clutch its lead position through 2026.

Market Participants / Key Players:

Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with the nuclear medicine are Eczacibasi-Monrol, Eckert & Ziegler Group, NTP Radioisotopes SOC Ltd., Mallinckrodt Pharmaceuticals, Australian Nuclear Science & Technology Organization (ANSTO), GE Healthcare, Nordion, Inc., Jubilant Life Sciences, The Institute of Radioelements, and Bracco Imaging S.p.A.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Research Methodology

Secondary research sources that are typically referred to include, but are not limited to company websites, annual reports, financial reports, broker reports, investor presentations, SEC filings, internal and external proprietary databases, relevant patent and regulatory databases, national government documents, statistical databases, market reports, news articles, press releases, webcasts specific to companies operating in the market, national government documents, statistical databases, and Factiva.

Primary research involves e-mail interactions, telephonic interviews, and face-to-face interviews conducted for each market segment across geographies. ARC conducts primary interviews on an ongoing basis with market participants and commentators in order to validate the data and analysis. Primary interviews provide firsthand information on market size, market trends, growth trends, competition landscape, and market outlook. These help validate and strengthen secondary research findings. They also help develop the analysis team’s expertise and market understanding.

VIEW FULL RESEARCH REPORT@ https://www.acumenresearchandconsulting.com/nuclear-medicine-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Nuclear Medicine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Nuclear Medicine Market By Product
1.2.2.1. Global Nuclear Medicine Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global Nuclear Medicine Market Revenue Share By Product in 2017
1.2.2.3. Diagnostics
1.2.2.4. Beta Emitters
1.2.2.5. Brachytherapy
1.2.2.6. Others
1.2.3. Nuclear Medicine Market By Application
1.2.3.1. Global Nuclear Medicine Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Nuclear Medicine Market Revenue Share By Application in 2017
1.2.3.3. Diagnostics
1.2.3.4. Therapeutics
1.2.3.5. Others
1.2.4. Nuclear Medicine Market by Geography
1.2.4.1. Global Nuclear Medicine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Nuclear Medicine Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Nuclear Medicine Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Nuclear Medicine Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Nuclear Medicine Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Nuclear Medicine Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Nuclear Medicine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Nuclear Medicine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Nuclear Medicine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Nuclear Medicine Major Manufacturers in 2017

CHAPTER 4. NUCLEAR MEDICINE MARKET BY PRODUCT

4.1. Global Nuclear Medicine Revenue By Product
4.2. Diagnostics
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Beta Emitters
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Brachytherapy
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Others
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. NUCLEAR MEDICINE MARKET BY APPLICATION

5.1. Global Nuclear Medicine Revenue By Application
5.2. Diagnostics
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Therapeutics
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA NUCLEAR MEDICINE MARKET BY COUNTRY

6.1. North America Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Nuclear Medicine Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE NUCLEAR MEDICINE MARKET BY COUNTRY

7.1. Europe Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC NUCLEAR MEDICINE MARKET BY COUNTRY

8.1. Asia-Pacific Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA NUCLEAR MEDICINE MARKET BY COUNTRY

9.1. Latin America Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST NUCLEAR MEDICINE MARKET BY COUNTRY

10.1. Middle East Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA NUCLEAR MEDICINE MARKET BY COUNTRY

11.1. Africa Nuclear Medicine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Nuclear Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Eczacibasi-Monrol
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Eckert & Ziegler Group
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. NTP Radioisotopes SOC Ltd.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Australian Nuclear Science & Technology Organization (ANSTO)
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. GE Healthcare
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Nordion, Inc.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Jubilant Life Sciences
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. The Institute of Radioelements
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Bracco Imaging S.p.A.
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Others
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1041

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.